Calcitonin gene-related peptide (CGRP) is a unique 37 amino acid peptide, which is encoded by the calcitonin gene.' The peptide has been identified in the central and peripheral nervous system such as in the heart and blood vessels and in the gastrointestinal tract, and in the pituitary and thyroid glands."' Little is known so far about the physiological roles of CGRP in man. Recently, CGRP receptors linked to activation of adenylate cyclase have been recognised in the cardiovascular system, and the peptide was shown to exert potent effects in man and rat which include positive chronotropic and inotropic effects on the heart and vasodilation.' Other effects involve the gastrointestinal tract which include inhibition of gastric acid secretion in rats, dogs, and man, '2 and dose dependent contraction of guinea pig ileal and colonic smooth muscles."3
creatic function.'4 To this end, CGRP has been localised immunohistochemically in nerve terminals of the islets of Langerhans and in islet cells.4' An action of CGRP on the human pancreas remains to be elucidated. Thus, effects of CGRP have been studied in normal human subjects in vivo on exocrine pancreatic secretion and on the release of islet cell hormones, and compared with those of calcitonin.
Methods

SUBJECTS
Nine healthy fasting male volunteers (mean age 26, range 23-34 years; average weight 78, range 62-91 kg) without history of gastrointestinal and endocrine disorders and not receiving any medication have been studied. All subjects gave written and informed consent to the studies undertaken. They were approved by the local Ethical Human Research Committee. Beglinger pmol/kg/h) were added to the infusion for the remaining 90 minutes of the experiments. The peptides were dissolved in 0-9% NaCl containing 0-.l% human serum albumin (wt/vol). The doses used have previously been shown to submaximally stimulate pancreatic secretion'6 '. Seventy five and 300 ng/kg/h (20 and 79 pmol/kg/h) CGRP, 300 ng/kg/h (88 pmol/kg/h) calcitonin, and control solutions (0-9'%o NaCI) were infused through indwelling catheters positioned in a forearm for the duration of the experiments (150 minutes). Blood samples were obtained in regular intervals at baseline and at 15 minute intervals during the experiments. Blood was collected in ice chilled lithium heparinised tubes containing 5000 KIU aprotinin/5 ml blood. Samples were immediately centrifuged at 4°C and the plasma stored at -20(C until assayed for pancreatic polypeptide (PP) and somatostatin by specific radioimmunoassays (RIAs). '9 Secretory volumes were measured to the next millilitre; bicarbonate concentration of the duodenal juice was determined by the back titration method,") trypsin by the method of Wiggins,"' amylase according to Rick Pancreatic islet cell secretion was stimulated with iv arginine.24 After an overnight fast, indwelling catheters were inserted into both cubital veins for blood sampling and for infusions, respectively. Thirty minutes later, blood samples were drawn at 15 minute intervals before, during, and after the administration of arginine-HCl (2.8 mmol/kg) diluted in 400 ml 0-9% NaCl as indicated in Figure 1 . On four different days, the subjects received either 0-9% NaCl (control), 75 or 300 ng/kg/h CGRP or 300 ng/kg/h calcitonin. Blood was collected as described above and assayed for insulin and glucagon by specific RIAs. slightly decreased pancreatic bicarbonate, trypsin and amylase output, but the difference did not reach statistical significance (p<0-1, Figure 2 ). The upper dose of CGRP (300/ng/h) and calcitonin, however, significantly reduced pancreatic trypsin and amylase secretion in response to the combined stimulation with secretin and caerulein (p<005 and p<001 respectively, Fig. 2 ). The decrease of pancreatic enzyme output brought about with 300 ng/kg/h calcitonin was of the same order than with 300 ng/kg/h CGRP.
EFFECTS OF CGRP AND CALCITONIN ON ISLET CELL FUNCTION
Basal PP concentrations were comparable and ranged from 4-8 to 7-2 pmol/l (Table 1) . Caerulein alone stimulated the release of PP (p<005). Calcitonin gene-related peptide and calcitonin did not affect basal PP concentrations. Stimulation of PP by caerulein was suppressed with calcitonin (p<001), whereas CGRP produced a minimal inhibition of PP concentrations which did not reach statistical significance (p<0-1).
Basal somatostatin concentrations were comparable in the different experiments (Table 1) . Neither CGRP nor calcitonin affected plasma somatostatin concentrations.
In the arginine infusion tests, basal insulin concentrations tended to decrease during the administration of calcitonin (p<O. 1) and remained unchanged during CGRP infusions. Arginine-stimulated insulin and glucagon release was unaffected by the administration of CGRP and calcitonin (Fig. 1) .
Fasting plasma glucose concentrations ranged from 3-8-4-8 mmol/l. In response to arginine infusions, plasma glucose increased significantly with the higher dose of CGRP and with calcitonin (p<0-05, Fig. 1 ), but the area under the curve of glucose concentrations did not show any significant difference from control experiments.
CARDIOVASCULAR EFFECTS OF CGRP AND
CALCITONIN
Intravenous administration of CGRP did not change the pulse rate and the arterial blood pressure in the dose range tested in any of the nine subjects (Table  2) . Cutaneous flushing of the face, the proximal thorax and occasionally of the palmar side of the hands was observed in all subjects with the higher dose of CGRP (300 ng/kg/h). Flushing disappeared within 30 minutes after termination of the CGRP infusions. Flushing was not recognised with 75 ng/kg/h of CGRP and no other side effects were noticed. Calcitonin did not produce changes in the pulse rate, arterial blood pressure, and no flushing was noticed. Heart rate CGRP (300 ng/kg/h) 69 (3) 68 (2) 68 (2) 69 (2) (2) 71 (2) 72 (3) 72 (2) NaCI (control)
72 (2) 71 (3) 72 (3) 73 (4) 73 (2) Data are mean (SE).
Discussion
The In conclusion, the present study has revealed that iv human CGRP, unlike in vitro, induces a small inhibition of exocrine pancreatic enzyme secretion in healthy volunteers, whereas the endocrine pancreas does not appear to be an important target for the peptide. Cutaneous flushing observed here and in previous studies"8 suggests important cardiovascular properties. We conclude that CGRP might be a regulatory peptide in the human gastrointestinal tract, but more studies are required to define its action and establish a physiological role. We thank Mrs Carita Frei for editorial assistance and for typing the manuscript. We 
